How India Exports Sorafenib to the World

In the United States, sorafenib received FDA approval under the brand name Nexavar on November 16, 2007, for the treatment of unresectable hepatocellular carcinoma. Subsequently, the FDA has approved multiple Abbreviated New Drug Applications (ANDAs) for generic versions of sorafenib, facilitating broader access to this critical medication. The presence of 203 active Indian exporters underscores the competitive landscape and the significant role of Indian manufacturers in supplying sorafenib to the U.S. market.

The European Medicines Agency (EMA) granted marketing authorization for Nexavar on July 19, 2006, for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma. (ema.europa.eu) Generic versions, such as Sorafenib Accord, received EMA approval on November 9, 2022. (ema.europa.eu) In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, ensuring that sorafenib products meet stringent EU Good Manufacturing Practice (GMP) requirements.

Sorafenib is included in the World Health Organization's Model List of Essential Medicines, highlighting its importance in treating specific cancers. The drug complies with international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, sorafenib is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for sorafenib to ensure affordability; however, the exact date of this pricing regulation requires verification from NPPA records. Export of sorafenib necessitates a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

The primary patent for sorafenib has expired, leading to increased generic competition globally. This has resulted in a more competitive market, with multiple manufacturers, including those from India, supplying sorafenib to various countries.

In June 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a new indication for Cabometyx (cabozantinib) for the treatment of adult patients with unresectable or metastatic neuroendocrine tumors. (ema.europa.eu) This development may influence treatment protocols and market dynamics for sorafenib.

In September 2019, the EMA's Committee for Orphan Medicinal Products (COMP) adopted a negative opinion on the orphan designation application for a combination of melatonin and sorafenib for the treatment of hepatocellular carcinoma, citing insufficient evidence of potential efficacy. (ema.europa.eu)

In November 2022, the EMA granted marketing authorization for Sorafenib Accord, a generic version of sorafenib, expanding the availability of this medication within the European Union. (ema.europa.eu)

In May 2019, the FDA approved Cyramza (ramucirumab) for the treatment of patients with hepatocellular carcinoma who have an alpha-fetoprotein of ≥400 ng/mL and have been treated with sorafenib, providing an additional therapeutic option for this patient population.

In January 2019, the FDA approved Cabometyx (cabozantinib) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib, further expanding treatment options in this area.

These developments reflect the evolving regulatory and therapeutic landscape surrounding sorafenib, with implications for market access, competition, and treatment strategies globally.

India's pharmaceutical industry, including the production of Sorafenib, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these critical components are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China.

Recent events have highlighted the vulnerabilities of this dependency. In October 2025, the U.S. Pharmacopeia reported that 58% of KSMs used for U.S.-approved APIs are sole-sourced from a single country, predominantly China. Such concentration poses a risk of supply interruptions, which can lead to production delays and increased costs for Indian pharmaceutical manufacturers.

Our proprietary trade data from 2022 to 2026 indicates that the top five exporters of Sorafenib from India account for 30.4% of the total export value, with TORRENT PHARMACEUTICALS LTD leading at 19.1%. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could impact global availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic production of APIs and reduce reliance on imports. While this initiative is a positive step, its effectiveness in diversifying the supplier base for Sorafenib remains to be fully realized.

The ongoing conflict in the Middle East, particularly the closure of the Strait of Hormuz since February 28, 2026, has severely disrupted global shipping routes. This strait is a critical passage for global trade, and its closure has led to significant delays and increased shipping costs. Major shipping companies have suspended transits through the region, opting for longer routes around the Cape of Good Hope, adding 10–14 days and up to $1 million in extra costs per trip.

These disruptions have cascading effects on the pharmaceutical supply chain, potentially delaying the export of Sorafenib from India to key markets, including the United States, which accounts for 75% of the export share. Additionally, the increased shipping costs may lead to higher prices for end consumers.

• Diversify API and KSM Sources: Encourage Indian pharmaceutical manufacturers to source APIs and KSMs from multiple countries to reduce dependency on any single nation.

• Enhance Domestic Production: Accelerate the implementation and expansion of the PLI scheme to strengthen domestic manufacturing capabilities for critical pharmaceutical components.

• Develop Alternative Shipping Routes: Invest in infrastructure and logistics to establish alternative shipping routes that bypass high-risk areas, ensuring more reliable delivery schedules.

• Strengthen Supplier Relationships: Foster long-term partnerships with a broader range of suppliers to enhance supply chain resilience.

• Implement Risk Monitoring Systems: Establish comprehensive monitoring systems to detect and respond to geopolitical and logistical risks promptly.

RISK_LEVEL: HIGH